The International Linked Clinical Trials Committee
The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.
The iLCT Committee
In Memoriam:
Professor John Trojanowski, who sat on Cure Parkinson’s International Linked Clinical Trials committee, sadly passed away in February 2021. Professor Trojanowski was an active and valued member of our iLCT programme and his knowledge and expert guidance will be sadly missed.
